Business context and reporting period
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies for age-related degenerative diseases of the central nervous system and retina. This Form 10-K reports the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter report. The company has no approved products and has generated no product-sales revenue. Its lead candidate, CT1812, is in Phase 2 development.
Financial performance and liquidity
Amounts below are in millions of dollars unless otherwise noted.
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Product-sales revenue | None | None | No commercial sales |
| Grant income | $24.8 | $22.2 | +$2.6 |
| Research and development expense | $37.2 | $30.3 | +$6.9 |
| General and administrative expense | $13.5 | $13.2 | +$0.3 |
| Total operating expenses | $50.7 | $43.6 | +$7.2 |
| Operating loss | $(50.7) | $(43.6) | Loss increased |
| Net loss | $(25.8) | $(21.4) | Loss increased $4.4 |
| Net loss per share, basic and diluted | $(0.86) | $(0.91) | Improved per share |
| Net cash used in operating activities | $(16.0) | $(18.5) | Cash use decreased $2.5 |
Grant income is reimbursement-based funding reported as other income, not product revenue. It partly offset operating losses. Higher clinical-trial and personnel costs drove most of the increase in R&D expense; manufacturing costs declined.
- Cash and cash equivalents were $29.9 million at year-end, down from $41.6 million. Total assets were $35.2 million and stockholders’ equity was $24.5 million.
- Management expected available cash, grant income and the net proceeds of the March 2024 offering to fund operating and capital needs through May 2025, assuming no draws from the remaining ATM or Lincoln Park facilities. This estimate depends on assumptions and may change.
- Cash flows used in investing activities were $0.1 million; financing activities provided $4.5 million. The company has not generated positive operating cash flow.
- Year-end liabilities included $0.5 million outstanding under insurance-premium financing and $0.7 million of operating lease liabilities. Total undiscounted operating lease commitments were $0.8 million. The filing reports no material litigation contingency.
- In March 2024, after year-end, the company completed an offering of 6.57 million shares and received approximately $10.4 million net. Year-end common shares outstanding were 32.17 million; approximately 39.0 million were outstanding as of March 22, 2024.
Gross or operating margins are not meaningful because the company has no product sales. No product revenue guidance or profitability outlook was provided.
Material developments, outlook and risks
- CT1812 trials: Enrollment was complete in the Phase 2 SHINE mild-to-moderate Alzheimer’s disease study; top-line results were expected in mid-2024. Recruitment had begun for START, a Phase 2 study intended to enroll up to 540 people with early-stage Alzheimer’s disease, supported by an approximately $81 million NIA grant. The company was also recruiting for the Phase 2 SHIMMER dementia with Lewy bodies study and had begun dosing in the Phase 2 MAGNIFY geographic atrophy study.
- Interim findings: An interim analysis of the first 24 SHINE participants reported a reduction in a CSF amyloid-beta measure and an approximately three-point difference in ADAS-Cog 11 decline versus placebo. The cognitive difference was not statistically significant (p=0.1295); a CSF amyloid-beta 42 finding at the 300 mg dose was reported as statistically significant. The company cautioned that the interim analysis was not powered to establish treatment differences. Separately, the completed SEQUEL study reported a statistically significant change in a central-region qEEG measure. These findings do not establish clinical efficacy or regulatory approval.
- Safety: CT1812 was described as generally well tolerated in reported trials. Some participants had asymptomatic, reversible liver-enzyme elevations; the company harmonized and increased monitoring where appropriate. Larger and longer studies may reveal additional safety issues.
- Funding and dilution: The company had received approximately $171 million in cumulative grants, primarily from the NIA, and reported approximately $67 million available from NIA funds for applicable future expenses at year-end. Grants reimburse eligible costs, are subject to conditions and audit, and may not cover all planned development. Further capital is expected to be needed; equity financing may dilute shareholders and grant funding may not continue.
- Development and execution risks: CT1812 remains investigational; the company has not conducted pivotal trials, and clinical results may differ from preliminary findings. Enrollment, regulatory requirements, manufacturing scale-up, third-party CRO and manufacturer performance, competition, reimbursement and access to capital could delay or prevent development or commercialization. CT1812 depends on single third-party suppliers for certain manufacturing steps.
- Other outlook: The company retains worldwide rights to CT1812 and may pursue collaborations, licensing or additional grant funding. No specific financial guidance was provided. The independent auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting as of December 31, 2023.
Important facts for investors to verify
- Whether final SHINE results support the interim biomarker and cognitive observations, and how effect sizes, statistical significance, endpoints and safety compare across treatment groups.
- Clinical-trial enrollment, timelines and outcomes for START, SHIMMER and MAGNIFY, including any changes to plans following regulatory discussions.
- Cash burn, grant reimbursement timing and eligibility, remaining grant availability, and the assumptions underlying the stated May 2025 cash runway.
- Future financing needs and potential dilution from the ATM, Lincoln Park equity line, stock awards or additional offerings.
- The filing’s differing SHINE enrollment descriptions: 153 participants in one trial description and 158 elsewhere; confirm the final enrolled population.